Phathom Pharmaceuticals (PHAT) Competitors $8.61 -0.30 (-3.37%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. IMVT, OGN, MIRM, AMRX, IBRX, XENE, BHC, GMTX, APLS, and ARWRShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Immunovant (IMVT), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors Immunovant Organon & Co. Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Immunovant (NASDAQ:IMVT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Which has more risk & volatility, IMVT or PHAT? Immunovant has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Do insiders & institutionals believe in IMVT or PHAT? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 5.9% of Immunovant shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is IMVT or PHAT more profitable? Immunovant has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -422.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.60% -71.89% Phathom Pharmaceuticals -422.42%N/A -90.11% Do analysts rate IMVT or PHAT? Immunovant presently has a consensus price target of $38.33, indicating a potential upside of 127.19%. Phathom Pharmaceuticals has a consensus price target of $17.50, indicating a potential upside of 103.25%. Given Immunovant's higher probable upside, equities research analysts plainly believe Immunovant is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer IMVT or PHAT? In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Immunovant. MarketBeat recorded 1 mentions for Phathom Pharmaceuticals and 0 mentions for Immunovant. Immunovant's average media sentiment score of 1.50 beat Phathom Pharmaceuticals' score of 1.27 indicating that Immunovant is being referred to more favorably in the media. Company Overall Sentiment Immunovant Positive Phathom Pharmaceuticals Positive Which has higher valuation & earnings, IMVT or PHAT? Phathom Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.74-6.16Phathom Pharmaceuticals$55.25M10.88-$334.33M-$5.24-1.64 SummaryPhathom Pharmaceuticals beats Immunovant on 8 of the 15 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$603.44M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.6521.2326.5720.02Price / Sales10.88280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book-2.327.498.065.50Net Income-$334.33M-$55.05M$3.15B$248.50M7 Day Performance-9.84%2.58%1.72%2.61%1 Month Performance73.94%5.22%3.92%5.42%1 Year Performance-16.00%5.04%35.02%20.76% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals4.067 of 5 stars$8.61-3.4%$17.50+103.3%-13.1%$603.44M$55.25M-1.65110Positive NewsIMVTImmunovant2.2361 of 5 stars$15.47-2.1%$38.33+147.8%-36.6%$2.64BN/A-5.65120Positive NewsOGNOrganon & Co.4.8243 of 5 stars$9.82+0.7%$18.00+83.3%-49.5%$2.55B$6.40B3.414,000Trending NewsMIRMMirum Pharmaceuticals3.4791 of 5 stars$50.28-0.1%$65.50+30.3%+45.8%$2.49B$336.89M-31.23140AMRXAmneal Pharmaceuticals3.3517 of 5 stars$7.91+1.2%$11.60+46.6%+28.0%$2.48B$2.79B-197.708,100IBRXImmunityBio2.074 of 5 stars$2.76-3.8%$12.25+343.8%-57.3%$2.44B$14.74M-4.76590XENEXenon Pharmaceuticals3.1844 of 5 stars$31.49-1.7%$54.82+74.1%-8.7%$2.42B$9.43M-9.75210BHCBausch Health Cos3.2525 of 5 stars$6.11-1.1%$7.42+21.4%+0.0%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+10.0%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5378 of 5 stars$17.62-0.4%$40.05+127.3%-49.1%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9385 of 5 stars$15.51+1.2%$43.71+181.8%-33.0%$2.14B$3.55M-11.08400Positive News Related Companies and Tools Related Companies Immunovant Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives ImmunityBio Alternatives Xenon Pharmaceuticals Alternatives Bausch Health Cos Alternatives Gemini Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
